Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter February 20, 2007

Lipid transfer protein activities in subjects with impaired glucose tolerance

  • Ulrich Julius , Matti Jauhiainen , Christian Ehnholm and Jens Pietzsch

Abstract

Background: Impaired glucose tolerance (IGT) is associated with an increased risk of atherosclerosis that may be due in part to dyslipidemia. The purpose of this study was to assess the regulatory role of lipid transfer proteins in the development of this dyslipidemia.

Methods: Activities of cholesterol ester transfer protein (CETP) and phospholipid transfer protein (PLTP), as well as lipid and protein components of the major lipoprotein fractions, were evaluated in probands with IGT and were compared with those in subjects with normal glucose tolerance. The effect of a fat-rich meal on these variables was also investigated.

Results: IGT probands had a higher triglyceride content in subfractions of low- (LDL) and high-density lipoprotein (HDL). IGT patients had higher fasting CETP activity. The latter was positively correlated with HDL2 triglycerides and negatively with HDL3 total cholesterol. PLTP activity and mass were not higher in IGT patients. However, PLTP activity correlated with components of VLDL and LDL and was influenced by the type of obesity. Neither CETP and PLTP activities nor PLTP mass were altered by a fat-rich meal. PLTP and CETP activities correlated in both fasting and postprandial conditions.

Conclusions: Increased fasting CETP activity may contribute to increased risk of atherosclerosis in subjects with IGT.

Clin Chem Lab Med 2007;45:237–43.

:

Corresponding author: Prof. Dr. Ulrich Julius, Medizinische Klinik und Poliklinik III, Universitätsklinikum Dresden, Fetscherstr. 74, 01307 Dresden, Germany Phone: +49-351-4582306, Fax: +49-351-4585306,

References

1. Ceriello A. Impaired glucose tolerance and cardiovascular disease: the possible role of post-prandial hyperglycemia. Am Heart J2004;147:803–7.10.1016/j.ahj.2003.11.020Search in Google Scholar

2. Laakso M, Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis1998;137(Suppl):S65–73.10.1016/S0021-9150(97)00314-6Search in Google Scholar

3. Gerich JE. Postprandial hyperglycemia and cardiovascular disease. Endocr Pract2006;12(Suppl 1):47–51.10.4158/EP.12.S1.47Search in Google Scholar

4. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med2004;164:2147–55.10.1001/archinte.164.19.2147Search in Google Scholar

5. Gao W, Qiao Q, Tuomilehto J. Post-challenge hyperglycaemia rather than fasting hyperglycaemia is an independent risk factor of cardiovascular disease events. Clin Lab2004;50:609–15.Search in Google Scholar

6. Qiao Q, Tuomilehto J, Borch-Johnsen K. Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia2003;46(Suppl 1):M17–21.10.1007/s00125-002-0932-4Search in Google Scholar

7. Schnell O, Standl E. Impaired glucose tolerance, diabetes, and cardiovascular disease. Endocr Pract2006;12(Suppl 1):16–9.10.4158/EP.12.S1.16Search in Google Scholar

8. Zhang YF, Hong J, Zhan WW, Li XY, Gu WQ, Yang YS, et al. Hyperglycaemia after glucose loading is a major predictor of preclinical atherosclerosis in nondiabetic subjects. Clin Endocrinol (Oxf)2006;64:153–7.10.1111/j.1365-2265.2005.02440.xSearch in Google Scholar

9. Petersen JL, McGuire DK. Impaired glucose tolerance and impaired fasting glucose – a review of diagnosis, clinical implications and management. Diab Vasc Dis Res2005;21:9–15.10.3132/dvdr.2005.007Search in Google Scholar

10. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care2001;243:447–53.10.2337/diacare.24.3.447Search in Google Scholar

11. Rye KA, Clay MA, Barter PJ. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis1999;145:227–38.10.1016/S0021-9150(99)00150-1Search in Google Scholar

12. Tall AR, Krumholz S, Olivecrona T, Deckelbaum RJ. Plasma phospholipids transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J Lipid Res1985;26:842–51.10.1016/S0022-2275(20)34314-5Search in Google Scholar

13. Jauhiainen M, Metso J, Pahlman R, Blomqvist S, van Tol A, Ehnholm C. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem1993;268:4032–6.10.1016/S0021-9258(18)53575-4Search in Google Scholar

14. Tu A-Y, Nishida HI, Nishida T. High density lipoprotein conversion mediated by human plasma phospholipid transfer protein. J Biol Chem1993;268:23098–105.10.1016/S0021-9258(19)49431-3Search in Google Scholar

15. Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL, et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest1999;103:907–14.10.1172/JCI5578Search in Google Scholar

16. Jaari S, van Dijk KW, Olkkonen VM, van der Zee A, Metso J, Havekes L, et al. Dynamic changes in mouse lipoproteins induced by transiently expressed human phospholipid transfer protein (PLTP): importance of PLTP in prebeta-HDL generation. Comp Biochem Physiol B Biochem Mol Biol2001;128:781–92.10.1016/S1096-4959(01)00297-4Search in Google Scholar

17. Oka T, Kujiraoka T, Ito M, Egashira T, Takahashi S, Nanjee MN, et al. Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. J Lipid Res2000;41:1651–7.10.1016/S0022-2275(20)31998-2Search in Google Scholar

18. Karkkainen M, Oka T, Olkkonen VM, Metso J, Hattori H, Jauhiainen M, et al. Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP). J Biol Chem2002;277:15413–8.10.1074/jbc.M112247200Search in Google Scholar PubMed

19. Bruce C, Chouinard RA Jr, Tall AR. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu Rev Nutr1998;18:297–330.10.1146/annurev.nutr.18.1.297Search in Google Scholar PubMed

20. The Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program. Diabetes Care 2005;28:2472–9.10.2337/diacare.28.10.2472Search in Google Scholar PubMed PubMed Central

21. Nauck MA, Meier JJ, Wolfersdorff AV, Tillil H, Creutzfeldt W, Kobberling J. A 25-year follow-up study of glucose tolerance in first-degree relatives of type 2 diabetic patients: association of impaired or diabetic glucose tolerance with other components of the metabolic syndrome. Acta Diabetol2003;40:163–72.10.1007/s00592-003-0106-ySearch in Google Scholar PubMed

22. Matthews DR, Hosker JP, Rudenski AS, Nayler BA, Treac DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia1985;28:412–9.10.1007/BF00280883Search in Google Scholar

23. Haffner SM, Kennedy E, Gonzales C, Stern MP, Miettienen H. A prospective analysis of the HOMA model: the Mexico City Diabetes Study. Diabetes Care1996;19:1138–41.10.2337/diacare.19.10.1138Search in Google Scholar

24. Jänis MT, Siggins S, Tahvanainen E, Vikstedt R, Silander K, Metso J, et al. Active and low-active forms of serum phospholipid transfer protein in a normal Finnish population sample. J Lipid Res2004;45:2303–9.10.1194/jlr.M400250-JLR200Search in Google Scholar

25. Pietzsch J, Julius U, Nitzsche S, Hanefeld M. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes1998;47:1928–34.10.2337/diabetes.47.12.1928Search in Google Scholar

26. Friedewald WT, Levi RI, Fredrickson DS. Estimation of the concentration of low density lipoproteins cholesterol in plasma without use of the ultracentrifuge. Clin Chem1972;18:499–502.10.1093/clinchem/18.6.499Search in Google Scholar

27. Syvänne M, Taskinen M-R. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet1997;350(Suppl 1):20–23.10.1016/S0140-6736(97)90024-6Search in Google Scholar

28. Frayn KN. Insulin resistance and lipid metabolism. Curr Opin Lipidol1993;4:197–204.10.1097/00041433-199306000-00004Search in Google Scholar

29. Pietzsch J, Julius U, Kirch C, Fischer S, Hanefeld M. Very low density lipoprotein (VLDL) overproduction is maximally expressed in early insulin resistant states. Ann NY Acad Sci1999;892:319–22.10.1111/j.1749-6632.1999.tb07807.xSearch in Google Scholar PubMed

30. Kissebah AH, Alfarsi S, Evans DJ, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes1982;31:217–25.10.2337/diabetes.31.3.217Search in Google Scholar

31. Hill SA, Thomson C, McQueen MJ. Cholesteryl ester transfer protein mutations, protein activity and HDL-cholesterol concentration. Clin Chem Lab Med1998;36:629–32.10.1515/CCLM.1998.110Search in Google Scholar PubMed

32. Ambrosch A, Mühlen I, Kopf D, Augustin W, Dierkes J, König W, et al. LDL size distribution in relation to insulin sensitivity and lipoprotein pattern in young and healthy subjects. Diabetes Care1998;21:2077–84.10.2337/diacare.21.12.2077Search in Google Scholar

33. Murdoch SJ, Carr MC, Hokanson JE, Brunzell JD, Albers JJ. PLTP activity in premenopausal women. Relationship with lipoprotein lipase, HDL, LDL, body fat, and insulin resistance. J Lipid Res2000;41:237–44.10.1016/S0022-2275(20)32057-5Search in Google Scholar

34. Colhoun HM, Taskinen MR, Otvos JD, Van Den Berg P, O'Connor J, Van Tol A. Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes. Diabetes2002;51:3300–5.10.2337/diabetes.51.11.3300Search in Google Scholar

35. Murdoch SJ, Carr MC, Kennedy H, Brunzell JD, Albers JJ. Selective and independent associations of phospholipid transfer protein and hepatic lipase with the LDL subfraction distribution. J Lipid Res2002;43:1256–63.10.1194/jlr.M100373-JLR200Search in Google Scholar

36. Cheung MC, Knopp RH, Retzlaff B, Kennedy H, Wolfbauer G, Albers JJ. Association of plasma phospholipid transfer protein activity with IDL and buoyant LDL: impact of gender and adiposity. Biochim Biophys Acta2002;1587:53–9.10.1016/S0925-4439(02)00054-6Search in Google Scholar

37. Dullaart RP, De Vries R, Scheek L, Borggreve SE, Van Gent T, Dallinga-Thie GM, et al. Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations. Scand J Clin Lab Invest2004;64:205–15.10.1080/00365510410005721Search in Google Scholar PubMed

38. Borggreve SE, De Vries R, Dullaart RP. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest2003;33:1051–69.10.1111/j.1365-2362.2003.01263.xSearch in Google Scholar PubMed

39. van Tol A. Phospholipid transfer protein. Curr Opin Lipidol2002;13:135–9.10.1097/00041433-200204000-00004Search in Google Scholar PubMed

40. Dullaart RP, van Tol A. Role of phospholipid transfer protein and prebeta-high density lipoproteins in maintaining cholesterol efflux from Fu5AH cells to plasma from insulin-resistant subjects. Scand J Clin Lab Invest2001;61:69–74.10.1080/00365510151068027Search in Google Scholar PubMed

41. Rashid S, Barrett PH, Uffelman KD, Watanabe T, Adeli K, Lewis GF. Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler Thromb Vasc Biol2002;22:483–7.10.1161/hq0302.105374Search in Google Scholar PubMed

42. Guerin M, Le Goff W, Lassel TS, Van Tol A, Steiner G, Chapman MJ. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol2001;21:282–8.10.1161/01.ATV.21.2.282Search in Google Scholar

43. Syeda F, Senault C, Delplanque B, Le Roy B, Thaminy A, Gripois D, et al. Postprandial variations in the cholesteryl ester transfer protein activity, phospholipid transfer protein activity and plasma cholesterol efflux capacity in normolipidemic men. Nutr Metab Cardiovasc Dis2003;13:28–36.10.1016/S0939-4753(03)80165-5Search in Google Scholar

44. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerosis cardiovascular disease. Nat Rev Drug Discov2005;4:193–205.10.1038/nrd1658Search in Google Scholar PubMed

45. Barter PJ, Kastelein JJ. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol2006;47:492–9.10.1016/j.jacc.2005.09.042Search in Google Scholar PubMed

46. Albers JJ, Cheung MC. Emerging roles for phospholipid transfer protein in lipid and lipoprotein metabolism. Curr Opin Lipidol2004;15:255–60.10.1097/00041433-200406000-00004Search in Google Scholar PubMed

47. Desrumaux CM, Mak PA, Boisvert WA, Masson D, Stupack D, Jauhiainen M, et al. Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells. J Lipid Res2003;44:1453–61.10.1194/jlr.M200281-JLR200Search in Google Scholar PubMed

48. O'Brien KD, Vuletic S, McDonald TO, Wolfbauer G, Lewis K, Tu AY, et al. Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis. Circulation2003;108:270–4.10.1161/01.CIR.0000079163.97653.CDSearch in Google Scholar PubMed

Published Online: 2007-02-20
Published in Print: 2007-02-01

©2007 by Walter de Gruyter Berlin New York

Downloaded on 28.3.2024 from https://www.degruyter.com/document/doi/10.1515/CCLM.2007.032/html
Scroll to top button